Related coverage linked through entity extraction aliases.
Apr 24, 2026
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
Apr 22, 2026
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Apr 07, 2026
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Mar 29, 2026
People with blood type B have a 28% higher risk of type 2 diabetes, while artificial sweetener consumption is linked to faster cognitive decline, particularly in younger adults and those with diabetes. The blood type finding comes from an umbrella review of 51 systematic reviews, while the sweetener study followed 12,772 Brazilian adults for eight years.
Mar 15, 2026
GLP-1 receptor agonists like semaglutide and tirzepatide help regulate appetite and improve satiety for medical weight loss. Clinical studies show patients can lose an average of 15% of body weight with these treatments. These medications are suitable for individuals with BMI of 27+ with weight-related conditions or BMI of 30+ regardless of other conditions.
Mar 18, 2026
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Mar 06, 2026
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
Feb 25, 2026
A clinical trial shows baduanjin, a traditional Chinese mind-body practice, reduces blood pressure by 3-5 points, comparable to first-line medications and brisk walking, with effects sustained for one year.
Feb 16, 2026
The FDA approved an oral version of Wegovy in December 2025, providing a pill alternative to injections. Clinical trials showed comparable effectiveness between oral and injectable forms of semaglutide for weight loss.
Feb 18, 2026
The Preeclampsia Foundation released a new educational resource to help OB-GYNs navigate predictive and diagnostic biomarker testing for hypertensive disorders of pregnancy, covering FDA-cleared tests from Thermo Fisher Scientific and Roche Diagnostics.
Feb 14, 2026
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
Feb 14, 2026
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
Feb 10, 2026
New research shows wearable devices can predict depression relapses weeks in advance through sleep pattern analysis, while studies reveal limitations in Apple Watch blood pressure alerts and benefits of replacing TV time with physical activity.
Feb 11, 2026
A trial at Tygerberg Hospital in Cape Town tested DM199, a drug originally developed for stroke, in pregnant women with severe preeclampsia. The drug stabilized dangerously high blood pressure after researchers found the effective dose in the 16th patient.
